BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21828189)

  • 21. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours.
    Mussurakis S; Buckley DL; Drew PJ; Fox JN; Carleton PJ; Turnbull LW; Horsman A
    Clin Radiol; 1997 Jul; 52(7):516-26. PubMed ID: 9240704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience.
    Kuhl CK; Jost P; Morakkabati N; Zivanovic O; Schild HH; Gieseke J
    Radiology; 2006 Jun; 239(3):666-76. PubMed ID: 16549623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging.
    Kvistad KA; Rydland J; Vainio J; Smethurst HB; Lundgren S; Fjøsne HE; Haraldseth O
    Radiology; 2000 Aug; 216(2):545-53. PubMed ID: 10924584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of whole-lesion histogram analysis of pharmacokinetic parameters in dynamic contrast-enhanced MRI of breast lesions with the CAIPIRINHA-Dixon-TWIST-VIBE technique.
    Li Z; Ai T; Hu Y; Yan X; Nickel MD; Xu X; Xia L
    J Magn Reson Imaging; 2018 Jan; 47(1):91-96. PubMed ID: 28577335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B
    Tsai WC; Kao KJ; Chang KM; Hung CF; Yang Q; Lin CE; Chen CM
    Radiology; 2017 Jan; 282(1):55-62. PubMed ID: 27479805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Chung WJ; Kim HS; Kim N; Choi CG; Kim SJ
    Radiology; 2013 Nov; 269(2):561-8. PubMed ID: 23878286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrimination between benign and malignant breast lesions using volumetric quantitative dynamic contrast-enhanced MR imaging.
    Cheng Z; Wu Z; Shi G; Yi Z; Xie M; Zeng W; Song C; Zheng C; Shen J
    Eur Radiol; 2018 Mar; 28(3):982-991. PubMed ID: 28929243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary breast abnormalities: selective pixel sampling on dynamic gadolinium-enhanced MR images.
    Mussurakis S; Gibbs P; Horsman A
    Radiology; 1998 Feb; 206(2):465-73. PubMed ID: 9457201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
    Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
    Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravoxel incoherent motion MR imaging for breast lesions: comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging.
    Liu C; Wang K; Chan Q; Liu Z; Zhang J; He H; Zhang S; Liang C
    Eur Radiol; 2016 Nov; 26(11):3888-3898. PubMed ID: 26863896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Separation of benign and malignant breast lesions using dynamic contrast enhanced MRI in a biopsy cohort.
    Kim SG; Freed M; Leite APK; Zhang J; Seuss C; Moy L
    J Magn Reson Imaging; 2017 May; 45(5):1385-1393. PubMed ID: 27766710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of clinical breast MR imaging performed with prototype computer-aided diagnosis breast MR imaging workstation: reader study.
    Shimauchi A; Giger ML; Bhooshan N; Lan L; Pesce LL; Lee JK; Abe H; Newstead GM
    Radiology; 2011 Mar; 258(3):696-704. PubMed ID: 21212365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
    El Khouli RH; Macura KJ; Kamel IR; Jacobs MA; Bluemke DA
    AJR Am J Roentgenol; 2011 Dec; 197(6):1498-505. PubMed ID: 22109308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural network approach to the segmentation and classification of dynamic magnetic resonance images of the breast: comparison with empiric and quantitative kinetic parameters.
    Szabó BK; Aspelin P; Wiberg MK
    Acad Radiol; 2004 Dec; 11(12):1344-54. PubMed ID: 15596372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity.
    Horsthuis K; Lavini C; Bipat S; Stokkers PC; Stoker J
    Radiology; 2009 May; 251(2):380-7. PubMed ID: 19401571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation.
    Gaens ME; Backes WH; Rozel S; Lipperts M; Sanders SN; Jaspers K; Cleutjens JP; Sluimer JC; Heeneman S; Daemen MJ; Welten RJ; Daemen JW; Wildberger JE; Kwee RM; Kooi ME
    Radiology; 2013 Jan; 266(1):271-9. PubMed ID: 23151823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newly Diagnosed Breast Cancer: Comparison of Contrast-enhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease.
    Lee-Felker SA; Tekchandani L; Thomas M; Gupta E; Andrews-Tang D; Roth A; Sayre J; Rahbar G
    Radiology; 2017 Nov; 285(2):389-400. PubMed ID: 28654337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
    Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
    Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractal Dimension Analysis of Pixel Dynamic Contrast Enhanced-Magnetic Resonance Imaging Pharmacokinetic Parameters for Discrimination of Benign and Malignant Breast Lesions.
    Sherminie LPG; Jayatilake ML
    JCO Clin Cancer Inform; 2023 Jan; 7():e2200101. PubMed ID: 36745858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.